Zevra Therapeutics (ZVRA) Change in Accured Expenses (2014 - 2026)

Zevra Therapeutics (ZVRA) has 13 years of Change in Accured Expenses data on file, last reported at -$529000.0 in Q1 2026.

• Quarterly Change in Accured Expenses rose 92.72% year-over-year to -$529000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$8.9 million (down 148.83% YoY) and the FY2025 annual result came in at -$15.6 million, down 333.21% from the prior year.
• Change in Accured Expenses fell to -$529000.0 in Q1 2026, from $412000.0 in the prior quarter.
• In the past five years, Change in Accured Expenses ranged from a high of $7.0 million in Q4 2024 to a low of -$7.3 million in Q1 2024.
• A 5-year average of -$320764.7 and a median of -$486000.0 in 2022 frame the typical range for Change in Accured Expenses.
• Annual changes were most pronounced in 2023 — Change in Accured Expenses surged 889.3% — and 2024, when it sank 290.46%.
• Tracing ZVRA's Change in Accured Expenses over 5 years: stood at $1.9 million in 2022, then surged by 206.58% to $5.7 million in 2023, then gained by 22.02% to $7.0 million in 2024, then slumped by 94.11% to $412000.0 in 2025, then plunged by 228.4% to -$529000.0 in 2026.
• The last three Change in Accured Expenses figures came in at -$529000.0 (Q1 2026), $412000.0 (Q4 2025), and -$4.7 million (Q3 2025), per Business Quant data.